Certified by Founder Lodge
NeoPhore Ltd
United Kingdom - Cambridge, Cambridgeshire
START UP
1 Disclosed Funding Rounds $12,245,712
0 Participating Investments
-
Founded date
2017
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantige
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| February, 02 ,2024 | Series B | $12,245,712 |
LIFTT
3B Future Health Fund I & II
NEVA SGR
Claris Ventures
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
